Catalyst Biosciences Performance
| CBIODelisted Stock | USD 0.41 0.02 4.65% |
The firm shows a Beta (market volatility) of -0.41, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Catalyst Biosciences are expected to decrease at a much lower rate. During the bear market, Catalyst Biosciences is likely to outperform the market. Catalyst Biosciences right now shows a risk of 0.0%. Please confirm Catalyst Biosciences maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to decide if Catalyst Biosciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Catalyst Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Catalyst Biosciences is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 44.3 M |
Catalyst |
Catalyst Biosciences Relative Risk vs. Return Landscape
If you would invest 41.00 in Catalyst Biosciences on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Catalyst Biosciences or generate 0.0% return on investment over 90 days. Catalyst Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Catalyst, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalyst Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catalyst Biosciences, and traders can use it to determine the average amount a Catalyst Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CBIO |
Based on monthly moving average Catalyst Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalyst Biosciences by adding Catalyst Biosciences to a well-diversified portfolio.
Catalyst Biosciences Fundamentals Growth
Catalyst Stock prices reflect investors' perceptions of the future prospects and financial health of Catalyst Biosciences, and Catalyst Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalyst Stock performance.
| Return On Equity | -2.69 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 51.03 M | |||
| Shares Outstanding | 37.97 M | |||
| Price To Earning | (0.34) X | |||
| Price To Book | 0.53 X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 794 K | |||
| EBITDA | (52.15 M) | |||
| Cash And Equivalents | 75.39 M | |||
| Cash Per Share | 2.39 X | |||
| Total Debt | 38 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | (0.78) X | |||
| Cash Flow From Operations | (33.1 M) | |||
| Earnings Per Share | (1.50) X | |||
| Total Asset | 28.44 M | |||
| Retained Earnings | (410.94 M) | |||
| Current Asset | 68.7 M | |||
| Current Liabilities | 37.76 M | |||
About Catalyst Biosciences Performance
By examining Catalyst Biosciences' fundamental ratios, stakeholders can obtain critical insights into Catalyst Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Catalyst Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California. Catalyst Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.Things to note about Catalyst Biosciences performance evaluation
Checking the ongoing alerts about Catalyst Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalyst Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catalyst Biosciences is not yet fully synchronised with the market data | |
| Catalyst Biosciences has some characteristics of a very speculative penny stock | |
| Catalyst Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 794 K. Net Loss for the year was (8.24 M) with loss before overhead, payroll, taxes, and interest of (64.91 M). | |
| Catalyst Biosciences currently holds about 75.39 M in cash with (33.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 28.0% of the company shares are held by company insiders |
- Analyzing Catalyst Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalyst Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Catalyst Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalyst Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalyst Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalyst Biosciences' stock. These opinions can provide insight into Catalyst Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |